文献速递流行病学与生物统计基础与转化研究

生存结局的多层网络Meta回归及其在非小细胞肺癌中的应用

Multilevel Network Meta-Regression With a Survival Outcome and an Application to Non-Small Cell Lung Cancer.
PubMed 文献 · Stat Med · 2026-01-01

针对个体参与者数据与聚合数据混合的间接比较场景,本文将多层网络Meta回归(ML-NMR)扩展至时间-事件结局,基于均值和中位生存构建贝叶斯估计方法,模拟显示性能满意;在早期非小细胞肺癌总生存案例中,利用SEER-Medicare数据模拟分析发现,有限切除联合辅助化疗较有限切除或肺叶切除不加辅助化疗延长生存。

要点

  • ML-NMR可整合IPD与AgD证据,在目标人群中比较任意治疗。
  • 本文将ML-NMR扩展至删失生存结局,基于参数生存模型进行贝叶斯估计。
  • 早期NSCLC案例中,有限切除联合辅助化疗较对照延长生存。

核心结论

  • 将ML-NMR扩展至时间-事件结局,模拟性能满意,案例支持有限切除联合辅助化疗延长早期NSCLC生存。

研究设计与样本

  • 方法学研究:考虑多种参数生存模型,基于均值和中位生存开发贝叶斯估计方法,并进行广泛模拟。
  • 案例研究:早期非小细胞肺癌总生存,对SEER-Medicare数据进行模拟分析。

主要发现

  • 广泛模拟显示所提出的ML-NMR方法性能满意。
  • 有限切除联合辅助化疗较有限切除或肺叶切除不加辅助化疗延长生存。

临床怎么用

  • 在仅有间接比较证据时,可用ML-NMR整合IPD与AgD进行生存结局的目标人群比较。

局限性

  • 现有ML-NMR研究多关注二分类和连续结局,删失生存结局研究有限,可能仅一项研究对AgD建模边际似然。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In biopharmaceutical studies, it is often of interest to compare the effects of two treatments (say, A and B), but data that contain a direct comparison are not available. However, there may be studies that compare them against another competitor (say, C). In this case, an indirect comparison of A versus B through C needs to be conducted. In this article, we consider the scenario where individual participant data (IPD) is available for the comparison of A versus C, but only aggregate-level data (AgD), for example, from a publication, is available for the comparison of B versus C. For such analysis, multilevel network meta-regression (ML-NMR) is advantageous since it can combine evidence from multiple trials with either IPD or AgD and can compare the treatments of interest in any target population. Most of the existing ML-NMR studies have focused on binary and continuous outcomes, while, relatively, research on censored survival outcomes remains limited with perhaps only one study modeling the marginal likelihood for AgD. Here, we aim to extend ML-NMR for time-to-event outcomes. We consider multiple popular parametric survival models and develop Bayesian estimation approaches built on mean and median survival. Extensive simulations show satisfactory performance. We further consider a case study on early-stage non-small cell lung cancer (NSCLC) overall survival. Emulation analyses of the Surveillance, Epidemiology, and End Results (SEER)-Medicare data are conducted. It is found that limited resection (LR) with adjuvant chemotherapy (ACT) prolongs survival compared to LR or lobectomy without ACT.

来源:Stat Med,查看原文。版权归原作者所有。

引用

  1. Jia R, Yi H, Teng Z, et al. Multilevel Network Meta-Regression With a Survival Outcome and an Application to Non-Small Cell Lung Cancer. Stat Med. 2026. PMID: 42687434. doi:10.1002/sim.70728

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。